ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2281

The Vasculitis Pregnancy Registry (V-PREG): Information from the First 3 Years

Jon Golenbiewski1, Kalen Young 2, Cristina Burroughs 3, Joyce Kullman 2, Peter Merkel 4 and Megan Clowse 5, 1Duke University Medical Center, Durham, NC, 2Vasculitis Foundation, Kansas City, MO, 3University of South Florida, Tampa, FL, 4University of Pennsylvania, Philadelphia, PA, 5Duke University, Durham

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: pregnancy and registry, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Reproductive Issues In Rheumatic Disorders Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: As outcomes for patients with vasculitis improve and treatments become less ovarian-toxic, more women with these diseases will become pregnant. How best to manage these pregnancies remains unclear and, given the rarity of these pregnancies, challenging to study. The Vasculitis Pregnancy Registry (V-PREG) is an online, patient-driven prospective pregnancy registry designed to collect observational data to increase our understanding of pregnancies in women with vasculitis [www.vpprn.org/VPREG].

Methods: V-PREG is imbedded within the online Vasculitis Patient-Powered Research Network (VPPRN), where members are asked to participate in this specific registry during pregnancy. Women with any form of vasculitis are eligible. All women indicate informed consent and are invited to complete online surveys at study entry, in each trimester, and post-partum. Women report pain, overall health, and vasculitis disease activity on a 0-10 visual analog scale (scores < 3 indicated minimal pain, vasculitis activity, or good health). Reminders to complete study surveys are sent to patients via repeated emails and phone calls.

Results: Between 11/2015-12/2018 62 pregnant women with one of several vasculitides enrolled in V-PREG (Table 1). Almost all women (95%) were diagnosed with vasculitis prior to conception and 67% (41/61) had been hospitalized for vasculitis at least once.  

Twenty-one women reported 52 prior pregnancies (Figure 1). Of these, 44% (n=23) resulted in a miscarriage, with losses reported among several vasculitides.  Additionally, 1 stillbirth and 1 elective termination were reported.

Of 36 pregnancies with data about the 3 months prior to conception, no women were hospitalized, 60% were taking immunosuppressive medications, 33% received glucocorticoids, and only one woman was taking a teratogenic medication (methotrexate). Self-reported vasculitis activity was generally low prior to conception with 83% reporting minimal pain, 75% good overall health, and 81% minimal vasculitis disease activity.

Of 32 pregnancies with first trimester data, 2 were hospitalized, 60% were taking immunosuppressive medications, and 40% received glucocorticoids. Self-reported vasculitis activity remained generally low with 78% reporting minimal pain, 72% good overall health, and 75% minimal or no vasculitis disease activity. There were no 1st trimester miscarriages.

Conclusion: V-PREG has successfully collected data on pregnancies among women with vasculitis.  Women with vasculitis report an unusually high rate of prior miscarriage ( >40%) compared to the average rate of approximately 15% for all pregnancies. The majority of current pregnancies occurred in women with minimal vasculitis activity and off of teratogenic medications, suggesting they were well-timed for success. Given the small sample size and method of enrollment it is not yet clear if these findings are a result of disease itself, treatment, or possibly reporting bias. Future directions include continued patient enrollment, enhancing data return, and launch of planned translations of V-PREG to substantially increase the number of patients enrolled in the registry.


Disclosure: J. Golenbiewski, None; K. Young, None; C. Burroughs, None; J. Kullman, None; P. Merkel, Abbvie, 5, AbbVie, 5, AstraZeneca, 2, 5, AstraZeneca,, 2, 5, Biogen, 5, Boeringher-Ingelheim, 2, 5, Bristol-Myers Squibb, 2, 5, Celegene, 2, 5, Celgene, 2, 5, ChemoCentryx, 2, 5, CSL Behring, 5, Genentech/Roche, 2, 5, Genetech/Roche, 2, 5, Genzyme/Sanofi, 2, 5, GlaxoSmithKline, 2, 5, InflaRx, 5, Insmed, 5, Jannsen, 5, Kiniksa, 5, Kypha, 2, TerumoBCT, 2, UpToDate, 7; M. Clowse, GSK, 2, UCB, 5.

To cite this abstract in AMA style:

Golenbiewski J, Young K, Burroughs C, Kullman J, Merkel P, Clowse M. The Vasculitis Pregnancy Registry (V-PREG): Information from the First 3 Years [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-vasculitis-pregnancy-registry-v-preg-information-from-the-first-3-years/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-vasculitis-pregnancy-registry-v-preg-information-from-the-first-3-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology